BioCardia, Inc. 8-K

What Happened

• On March 3, 2026 BioCardia, Inc. announced and furnished a press release reporting late-breaking echocardiography results from its Phase III clinical trial for ischemic heart failure with reduced ejection fraction (HFrEF). The results were presented by Dr. Amish Raval, M.D., Professor of Medicine at the University of Wisconsin and National Co-Principal Investigator of the CardiAMP HF Trial, in the late-breaking clinical trial oral presentation session at the Technology and Heart Failure Therapeutics conference. The press release is included with the Form 8-K as Exhibit 99.1.

Key Details

• Filing date: March 3, 2026 (Form 8-K, Item 7.01 Regulation FD disclosure).
• Trial: Phase III clinical trial for ischemic HFrEF (CardiAMP HF Trial).
• Presentation: Late-breaking echocardiography results presented by Dr. Amish Raval at the Technology and Heart Failure Therapeutics conference.
• Disclosure: Press release attached as Exhibit 99.1 to the Form 8-K.

Why It Matters

• Clinical data from a Phase III trial is a material development for a biotech company; new echocardiography results may influence investor views on the trial’s safety and efficacy profile and the company’s clinical progress.
• The presentation at a scientific conference signals peer visibility and may lead to broader attention from clinicians, regulators, and investors.
• The filing provides the official disclosure of these results—investors should review the press release for details and watch for further trial updates, regulatory filings, or financial disclosures that could affect the company’s outlook.